arrow_back Back

ARCA

SKU: N-7003

Description

Trusted TriLink quality, exceptional price. A key step in cellular mRNA processing is the addition of a 5' cap structure, which is a 5'-5' triphosphate linkage between the 5' end of the RNA and a guanosine nucleotide. The cap is methylated enzymatically at the N-7 position of the guanosine to form mature mCAP. When preparing synthetic mRNA, the cap is often added prior to use in order to stabilize the mRNA and significantly enhance translation. Using a 4:1 mixture of a cap analog to GTP in transcription reactions will cap 80% of the resulting mRNAs. If mCAP (pre-methylated CAP) is used, only half of the asymmetrical mCAP will insert in the functional orientation. ARCA can only insert in the correct orientation, resulting in mRNAs that are translated twice as efficiently. TriLink is the least expensive source of high quality ARCA. We also offer CAP and mCAP for more traditional capping reactions.

Product details


Catalog No	N-7003
Purity	≥95% by AX-HPLC
Extinction Coefficient	21
Molecular Formula	C₂₂H₃₂N₁₀O₁₈P₃ (free acid)
Molecular Weight	817.40 g/mole (free acid)
Salt Form	NH4+
Concentration	100 mM
Buffer	H₂O
Recommended Storage	-20°C or below
Application	CRISPR
Backbone	5'-5'-Triphosphate
Base Analog(s)	Guanosine
Nucleotide Category	Cap analogs
Cap Analogs	Other
Shipping Temp	Frozen

Technical documents

Safety Data Sheet Look-up

Product FAQs

They both utilize co-transcriptional capping but differ in the following ways.

Cap structure: ARCA forms a cap-0 structure, which is not recognized as "self" in higher eukaryotes and can trigger unwanted immune responses. CleanCap analogs, on the other hand, form a Cap-1 structure, which is naturally found in higher eukaryotes and thus better controls reactogenicity and improves protein translation.

Transcriptional start site: ARCA's dinucleotide structure (^m7GpppG) means that transcription inherently starts with guanosine (G). CleanCap analogs are trinucleotides (^m7GpppA_mG for mRNA and ^m7GpppA_mU for saRNA) and bind to the +1 and +2 nucleotides downstream of the T7 promoter, incorporating an AG start site in mRNA and an AU start site in saRNA.

GTP competition: ARCA, as a guanosine dimer, competes with free GTP during the in vitro transcription reaction, which can lower both efficiency and yield of capped RNAs. CleanCap analogs, with their AG or AU start site, avoid competition with GTP, eliminating the need for NTP starvation and improving both capping efficiency and RNA yield.

Certificate of analysis

Certificate of Analysis (CoA)

Intellectual property

Products are for research use only, not for use in diagnostic or therapeutic procedures or for use in humans. Products are not for resale without express written permission from TriLink No license under any patent or other intellectual property right of TriLink or its licensors is granted or implied by the purchase unless otherwise provided in writing.

TriLink does not warrant that the use or sale of the products delivered hereunder will not infringe the claims of any United States or other patents or patents pending covering the use of the product alone or in combination with other products or in the operation of any process. All and any use of TriLink product is the purchaser's sole responsibility.

Pseudouridine-5'-Triphosphate N-1019
5-Methylcytidine-5'-Triphosphate N-1014